• PI3K Inhibitor Fails to Pass Muster With FDA Advisory Committee

    6 days ago - By MedPageToday

    The FDA's Oncologic Drugs Advisory Committee made a clean sweep of its 2-day meeting, deciding that the PI3K inhibitor duvelisib does not offer a favorable risk-benefit ratio for patients with chronic lymphocytic...
    Read more ...